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PARTICULATE SYSTEMS AS CARRIERS FOR SITE-SPECIFIC DRUG 
DELIVERY: THE STATE OF THE ART 
D.J.A. Crommelin 
In the last decade a number of particulate carrier systems 
have been developed to change the therapeutic efficacy of 
drugs after intravenous injection. Among these are nanopar- 
t i t les ,  liposomes, gelatin and albumin microspheres. The ob- 
jectives for designing these systems varied widely: from a 
sustained action to site specific delivery of the encapsu- 
lated drug. 
Critical points for the selection of a carrier system are: 
I) the ab i l i ty  of the carrier-homing device combination to 
deliver the drug at the desired sites; 2) the acute and 
chronic toxic i ty of these systems and their immunogenicity; 
3) the preparation and shelf l i fe  of the products. 
For homing devices antibodies and certain glycolipids are 
under investigation. The results indicate that site speci- 
f ic delivery is hampered by the limited ab i l i ty  of the car- 
riers to pass the wall of the blood vessels and the strong 
a f f in i ty  of the cells of the reticulo-endothelial system 
(RES) for these "foreign" bodies. Therefore, target sites 
should be located either in the compartment of injection 
(general circulation) or in the cells of the RES. 
Distribution kinetics in vivo are susceptible to composi- 
tion, size and charge of the Carrier system. A proper de- 
f in i t ion  of the product is therefore essential to obtain 
results that are suff ic iently reproducible. 
In this presentation some of the conclusions mentioned 
above wil l  be i l lustrated and discussed in more detail. 
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DRUG TARGETING: FACT OR FICTION ? RECEPTOR MEDIATED ENDO- 
CYTOSIS AS A POTENTIAL MECHANISM FOR TISSUE-SPECIFIC DRUG 
DELIVERY 
D.K.F. Meijer 
An increased drug selectivitv can in principle be obtained 
by covalently linking of drugs to a blodegradable carrier. 
The par t i cu la r  macromolecule should be spec i f i ca l ly  recog-  
n ized by receptors  for  endocytos i s  on the ce l l  sur face  of  
the organ or t i ssue  where the drug i s  requ i red  for  i t s  ac-  
t ion .  A loca l  drug de l ivery  of  potent ia l l y  very tox ic  com- 
pounds may not only decrease undes i rab le  s ide  e f fec ts  and 
tox icL ty  on o ther  t i ssues  ( "pass ive  ta rget ing" ) ,  but can 
a l so  produce a marked increase  in potency of the drug 
( "act ive  ta rget ing" ) .  The s impl i c i ty  of  the drug target ing  
concept however i s  inverse ly  re la ted  to the complex i ty  in 
the proper  des ign  of therapeut ic  dosage forms for  human use.  
Apart from pharmaceut ica l  problems such as chemical  s tab[ -  
l i ty ,  p ract i ca l  routes  of admin is t ra t ion  and costs  of  manu- 
fac tur ing ,  chron ic  tox ic i ty  on the RES system as we l l  as 
poss ib le  immunogenic i ty  have to be taken in to  account .  In 
add i t ion ,  the in t race l lu la r  fa te  of  the drug-car r ie r  complex 
not only in normal but a l so  in heterogenous  patho log ica l  
t i ssue  should be c lear ly  de f ined  before  ra t iona l  c la ims  of 
improved drug spec i f i c i ty  can be made. Examples are hepato -  
t rop ic  car r ie r - sys tems for  ant [v i ra l  agents  d i rec ted  to 
v i ra l  hepat i t i s ,  ant ip ro tozoa l  compounds (malar ia  e tc . ) ,  
ant [neop las t i c  agents ,  enzymes for  t reatment  of genet ic  
enzyme def~q lenc ies ,  exogenous cho les tero l  to man ipu la te  
cho les tero l  synthes is ,  d iphter ia  tox in  to inh ib i t  p ro te in  
synthes is ,  fo l in ic  ac id  to " rescue"  hepatocytes  from gene- 
ra l  tox ic i ty  of methot rexate  and probes for  tes t ing  hepat ic  
lysosomal  funct ion .  In teres t ing ly  some of these des igns  can 
be ext rano la ted  to o ther  t i ssues  and may wel l  reach the 
s tage  of c l in i ca l  tes t ing .  I t  i s  concluded that  the research  
of  drug ta rget ing  requ i res  a mul t id i sc ip l inary  ce l l  b io lo -  
g ica l  as wel l  as an in tegra l  pharmaceut ica l  approach to 
guarantee  pract i ca l  so lu t ions  to the very complex problems 
in th i s  area .  
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MACROMOLECULAR PRODRUGS OF ADRIAMYCIN 
C.J.T. Hoes W, W.A.R. van Heeswijk*, B. de Grooth § J. Mud +, 
J. Oreve + and J. FelJen* 
SUMMARY 
The anthraeycline antibiotics daunomycln and 14-hydroxydau- 
nomyctn (adrlamycin, ADR) are very effective in the treat- 
ment of a number of malignancies. However, due to cardio- 
toxic side effects the cumulative dose may not exceed a 
certain value. We are developing ADR-polymer eonjugates 
(1,2) with the alm Of improving the therapeutic index by 
using the concept of the lysozomotroplc prodrug. A plasma- 
stable polymer-bound drug is internalized by cells by pino- 
cytosls and degraded In the lysozomal compartments by many 
digestive enzymes at an acidic pH (pH 4-5) releasing the 
free drug. 
We prepared a series of amlnorlbosyl-bound prodrugs of ADR 
using poly(a-L:glhtamle aeid), PGA as a carrier and di f fer-  
ent pepttdes as spacers (1,2). The eonjugates were studied 
for their capacity to inhibit the growth of mouse leukemia 
L1210 an T mouse melanoma B16 cells (1,2). The cytotoxlc 
act lv i ty lo f  the conjugates increases with increasing length 
of the spacer, but remains below (I-10%) that of free ADR. 
Our current studies include the plnocytosis of some of the 
ADR-polymer conjugates into cells using laser flow cyto- 
merry and'laser microscopy as well as the release of ADH 
effected by papain as a representative nzyme for lysozomal 
enzymes. These studies may allow the optimization of the 
release of ADR from polymeric prodrugs. 
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